Downstream Processing and Biopharmaceutical Products

Key Insight

Biological products are essential for applications spanning biotransformations, diagnostics, R&D, and the food, pharmaceutical, and cosmetic industries. While some uses tolerate crude extracts, biopharmaceuticals demand exceptional purity, making downstream processing a critical production component. Regulatory guidelines stipulate that the production process defines the biopharmaceutical product, necessitating precise and efficient downstream step definition early in development. Blood plasma fractionation, the first large-scale biopharmaceutical industry established over 50 years ago, currently produces 100 tons annually, primarily using precipitation with organic solvents, although chromatographic separation processes are now also integrated. Early biopharmaceuticals also included anti-venom antibodies and antitoxins from animal sources, purified through a combination of precipitation, filtration, and chromatography.

Today's biopharmaceuticals are almost exclusively manufactured using recombinant DNA technology, with chromatography and membrane filtration serving as the main purification methods. In 2006, market data showed that approximately one-third of biopharmaceuticals were antibodies or antibody fragments, nearly 20 percent were erythropoietins, and 14 percent were insulins, with the remaining market share held by enzymes, growth factors, and cytokines. Proteins are expected to remain the dominant biopharmaceuticals due to their advantageous properties, including being well-tolerated, highly potent, and often possessing a long half-life after administration, which makes them effective therapeutics.

However, protein applications in cosmetics are complicated by legal frameworks in the U.S. and Europe, which do not permit pharmacologically active compounds in cosmetic products. Consequently, very few proteins are currently employed in this sector. The most notable example is botulinum toxin, or 'Botox,' used for skin care. These and similar compounds are exclusively administered by physicians and are therefore not categorized as cosmetics, according to regulatory definitions.